Simranjit Singh is the CEO of Guardant Health, a precision oncology company that launched the first FDA-approved blood test for genomic testing across all solid cancers about 2 years ago. And just recently, Guardant Health AMEA was involved in a partnership with Adicon Holdings Limited, a leading independent clinical laboratory company based in China, to boost global research and diagnostic oncology efforts. Simranjit Singh joins Michelle Martin on Money and Me as he gives a breakdown of Guardant’s portfolio and efforts to effectively revolutionise the continuum of cancer care and improve clinical outcomes for cancer patients.

Money and Me: Upclose with Centurion Accommodation REIT
18:57

Market View: Shocks from Middle East fallout, the logistics giant raking in the bucks , AI Bets in China and Novo Nordisks higher dose weight-loss drug approval and its share price.
25:50

Money and Me: Why are markets still climbing if oil prices are rising?
23:15